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The medical device industry is a significant and major contributor to global health, yet innovation and research
remains suboptimal. Current data focuses on devices, recalls and economics without genuine reflection on health
impact and outcomes. Additionally, current understanding of medical device innovation and regulation has
provided recommendations that have yet to be implemented. The medical device industry has ample opportunity
to transform. Recommendations in strengthening pre and post market data, clinical trial parameters and impact,
measurement of health outcomes and global surveillance can advance this transformation. Acknowledgement of
ongoing successes in reform, such as device exemption approval turnaround times, can be a catalyst for the larger
industry. Health service and outcome research, improved policies and application of recommendations can
transform medical devices for best practice and optimal global health.
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Commentary
There are many choices as well as solutions to be con-
sidered in healthcare. Decisions about change and best
practice are formed over consensus and debate of these
options. For the medical device industry, the debate has
been unnecessarily long and ongoing. The medical
device industry and regulation must change without
further delay.
Medical devices are critical for the advancement of
healthcare and they create immense economic impact.
In 2009, the United States medical device industry rev-
enue totaled $146 billion. Throughout the decade from
2000–2010, there were 30,000 medical devices cleared
by the Food and Drug Administration (FDA) [1]. It is an
industry that continues to grow, with both large and
small company interest.
The regulation of medical devices varies by country.
The United States has tasked the FDA with the responsi-
bility of assurance of safety and effectiveness of medical
devices, allowing the FDA full authority of device ap-
proval. The Pharmaceuticals and Medical Devices
Agency (PMDA) has similar authority in Japan, and
China has recently created the China Food and Drug
Administration (CFDA). In Europe, devices can be
marketed after a Notified Body (NB) evaluates the de-
vice. NBs are for-profit, private organizations and are
overseen by individual country Competent Authority
(CA) regulators. There is no EU equivalent to medical
device administration oversight such as the FDA or
CFDA, and no EU equivalent or medical device over-
sight similar to medicine oversight at the European
Medicines Agency (EMA) [2]. In Latin America, medical
devices are regulated by various ministries of health and
public health administrators [3]. Overall, public interest
by foundation and structure in medical device approval
is present in many countries, but the enforcement, ana-
lytics, approval and post-marketing surveillance varies
[4]. Countries that have universal national health plans
are afforded government oversight, and thus government
accountability, in device regulation. This translates into
optimal choice for medical device in reimbursement, an
alternative mechanism of regulation [5].
Level of regulation based on risk of device is the
method classification in multiple countries. This classifi-
cation system varies by individual nations, however.
Additionally, approval processes based on these risk
classifications are of debate. Premarket approval require-
ments in the United States are based on classes, and
even a review of the highest risk classification showed
only 79% of the riskiest devices underwent premarketCorrespondence: jbabyar@gmail.com
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approval. Other countries also have varying levels of
missed opportunities in premarket approval require-
ments [1].
Post market surveillance is assisted by adverse event
reporting. For the FDA, the Medical Device Reporting
(MDR) is the designated system. In Europe, it is the
Eudamed [1]. Focus of the FDA has been moving toward
post market evaluation as opposed to pre market analyt-
ics [5], in part due to clinical trial appropriateness and
reliability. Likewise, when clinical trials are of less im-
portance, there is less drive from industry to perform
them [1]. Understanding these dynamics can move con-
sensus forward.
There are well documented recommendations to
transform the medical device industry while optimizing
safety and public health priority. Ongoing expert con-
sensus and reports should drive this transformation,
with industry and regulation cooperation and without
delay.
Scope and understanding of clinical trial research
within the medical device industry must be reviewed by
understanding the differences in regulation between
devices and pharmaceuticals. Pharmaceuticals are
brought through four different stages of clinical trials,
receive approval for marketing in the United States [6]
and also receive classification in conjunction with the
Drug Enforcement Administration (DEA). The entire
drug development process may take 8–10 years. Devices
are given classification by the FDA, with limited pre-
market clinical trial data. Post-market surveillance, how-
ever, is lengthier for devices. Both drug and devices must
get approval from the FDA before marketing to the
public, both must comply with regulations and ethical
conduct, and both have means for humanitarian use.
Unlike drug manufacturers, however, device manufac-
turers are not often inspected by the FDA. Additionally,
all drugs must prove safety and efficacy for the public,
while only class III devices are required to do so [6].
Clinical trials provide understanding into a device’s
impact over time on human individual health. There is
great debate in the medical device industry over clinical
trials, as population testing before approval may not be
appropriate and matched sample populations may not
be feasible. It is difficult to randomize clinical trials for
devices that are for specialty care, and in populations
that cannot be blinded or unbiased. Additionally, long-
term clinical trial data is often not collected. The FDA
requires one pivotal and one non pivotal study for device
approval, at minimum. A recent review of clinical trials
found that the majority of devices have been approved
with these minimal requirements, though some compan-
ies have ongoing studies throughout the device lifespan
[7]. Regulatory bodies are left with the burden of navi-
gating grey areas in approval and current accepted “best
practices” in clinical trials. Literature can be found on
recommendations, with some suggesting device com-
panies work toward the optimal clinical trial design and
others suggesting cultural and understanding of clinical
trial design be reformed. Recommendations also include
the consideration that long term data is crucial to under-
stand the device, safety and effectiveness, and can pro-
vide insight into new considerations and uses for the
device [7].
Definite and concrete change to clinical trial data re-
quirements require an appreciation for flexibility. With
an increased attention to cost effectiveness and com-
parative effectiveness in health policy and reimburse-
ment, the industry has sought to strengthen post-market
technique in surveillance. It is crucial to remain vigilant
in pre-market clinical studies, however. While often dif-
ficult to implement in comparison to drug trials, device
clinical trials require flexibility. Too, while appropriate
design for one device clinical trial may not be appropri-
ate for another, fundamentals and best practice ap-
proaches should be promoted. Industry and academia
expertise can be complimented by national and inter-
national regulatory guidance in consideration of best
practices in clinical trial design. While clinical trials in
medical devices may not be able to provide double-
blinded advantage, endpoint assessments in patient qual-
ity of life and subjective responses are valuable for the
industry [7]. In ongoing evaluations, masking the investi-
gator will allow distinct advantage in these newly consid-
ered endpoints. Additionally, randomization of specific
devices may not be feasible but randomization of prod-
uct or software additions may be. There is ample room
for flexibility in clinical trial design and best practices,
but clinical trials must be encouraged rather than viewed
as irrelevant in the medical device industry. Clearly, the
importance of clinical trial data cannot be overestimated.
Recall data should drive process change in regulation.
Recalls of medical devices increased from 2003–2012 in
the United States, with the most common reason being
device design failures. Within the design of devices, fail-
ures and issues with software are problematic. Other
common causes of recalls include non-conforming ma-
terials and component issues [8]. In instance, 71% of
high-risk recalls in the United States were originally ap-
proved by the 501 k process [1]. 18% of medical devices
through 501 K have been part of high and moderate risk
recalls in recent years [5]. Approval processes accom-
panied by stronger post-market surveillance can assist in
better outcomes with recalls, but new strategies for
medical device regulation must also be introduced.
Benchmarks should be set by independent authorities so
that the collective medical device industry, along with
regulators and governments, meet identified standards
set with recalls. Using data can assist in the argument
Babyar Safety in Health  (2017) 3:5 Page 2 of 4
for sustained change to regulation processes and may
even assist in reduction of device recalls altogether In
fact, the FDA has stated that working alongside industry,
medical device recalls may be decreased by as many as
400 annually [8].
The differences in regulatory requirements between
drugs and devices should be sound in evidence.
Additionally, differences should be compared with
international peers and system improvements should be
implemented globally. Use of patient outcomes and com-
parative effectiveness research may aid in these decisions.
Should strong evidence for or against current differences
in drugs and device regulations present, revision in regula-
tor and industry practices should follow suit.
Consumption of medical devices also differs greatly by
country, but this consumption is not accurately or con-
sistently documented in much literature. Correlation be-
tween medical device consumption, physical health
outcomes and quality of life must be addressed. While
an extensive undertaking, partnerships between public
health, government and industry are already present. As
the medical device industry expands within high-use
populations as well as in new markets and new
boundaries, post-market reporting will grow. As such,
true correlation and significance of medical device and
outcomes can be researched, measured and can assist in
policy and regulatory formation. In fact, it has been
reported that some reform measures in Europe are
already seeking to shape policy around public interest
and device impact. Outcome understanding is the ideal
approach, and it is within grasp.
Speculative commentary on industry and government
regulatory job movement is widespread in literature and
media. Commentary on lobbying and lawmaker deci-
sions that favor the device industry is also common. Yet,
full analyses is not allotted. Criticism and innuendo
cause friction in trust and alarm in medicine. Re-
searchers should analyze all factors that weigh decisions
from government administration, and transparency in all
facts is helpful. Recent policy changes in the United
States that reflect physician disclosure with company
partnerships is a wonderful step, other countries should
follow suit and future decision making should strive for
similar transparency.
Ongoing improvements should be celebrated and set
as example for future change. Too, these improvements
are contingent on full commitment, which means that
policy and regulation changes must be accompanied by
thorough enforcement and research. Unique identifier
requirements on devices are an example of positive
change for surveillance, contingent on enforcement and
vigilance in process. Another example of positive change
is the FDA approval of Investigational Device Exemption
(IDE), which took an average of 400 days in 2001 but
was reduced to 30 days in 2015 [9]. Health service re-
search should investigate and support health outcomes
alongside shortened approval times, assuring staff and
administration that what may feel like carelessness is
not. Similar efforts nationally and internationally, as well
as strategic plan objectives met, should be applauded.
Conclusions
The medical device industry is a major player in health-
care. Medical device impact, from individual health to
collective economy, is immense. Driving change starts
with acknowledgement of current recommendations for
improvement as well as swift implementation of these
ideals, including regulation, surveillance and global data
collaboration. Health service and outcome research, im-
proved policies and application of recommendations can
transform medical devices for best practice and optimal
global health.
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